Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Coplanar VMAT versus HyperArc: a comparative study in brain metastases stereotactic radiosurgery.

Created on 21 Nov 2026

Authors

Riccardo Ray Colciago, Valeria Faccenda, Roberta Muni, Lorenzo De Sanctis, Giulia Rossano, Federica Ferrario, Claudia Bianchi, Sara Parabicoli, Suela Vukcaj, Stefano Andreoli, Gian Luca Poli, Elena De Ponti, Maurizio Giovanni Agostino Portaluri, Denis Panizza, Stefano Arcangeli

Published in

La Radiologia medica. Nov 20, 2026. Epub Nov 20, 2026.

Abstract

Clinical outcomes of stereotactic radiosurgery (SRS) performed with two different techniques across two institutions-coplanar volumetric modulated arc therapy (VMAT) and HyperArc-were compared.
Data from two cohorts of patients at two institutions between January 2021 and December 2024 were retrospectively analyzed. Patients were eligible if they received ablative treatment for up to 10 brain metastases at first irradiation. Prescriptions were 14-21 Gy in one fraction, 18-27 Gy in 3 fractions. Treatments delivered in 5 or more fractions were excluded from the analysis. The primary endpoint was local control (LC). Secondary endpoints were intracranial disease-free survival (iDFS) and overall survival (OS). Univariate and multivariate Cox proportional hazards models were applied to explore potential predictors of outcomes.
A total of 126 consecutive patients with 296 brain metastases were analyzed, with a median follow-up of 8 months (range: 0-40). Baseline characteristics were balanced between the two cohorts. At the lesion level, 173 metastases (58.4%) were treated with VMAT and 123 (41.6%) with HyperArc. Median gross tumor volume (GTV) was significantly lower in the VMAT group (p = 0.003). The median dose to 95% of the GTV was slightly above 100% of the prescription in most treatments for both the cohorts. Local progression occurred in 16 lesions (5.4%), distributed as 4.6% for VMAT and 6.3% for HyperArc, with a median time to progression of 8 months (range, 0-40). The 1-year actuarial LC rate for the whole cohort was 89.9% (95% CI, 87.3-92.6), with no statistically significant differences between the use of VMAT or HyperArc (p = 0.70). At univariate analysis, higher BED values were significantly associated with improved LC (p < 0.05). Specifically, BED ≤ 59.8 Gy to 95% of the GTV was significantly associated with inferior LC. The 1-year actuarial iDFS and OS were 51.7% and 50.2%, respectively, with no significant differences between VMAT and HyperArc (p = 0.84 and p = 0.23, respectively). In multivariate analysis, poor performance status and synchronous metastases were associated with worse OS.
In this retrospective two-institution cohort, local control did not differ significantly between coplanar VMAT and HyperArc. These findings support the feasibility of both approaches but do not establish clinical equivalence. Ablative dose prescription should be individualized according to patient and tumor characteristics while respecting normal tissue dose constraints. Differences in toxicity, particularly radiation necrosis, remain unknown.

PMID:
43062787
Bibliographic data and abstract were imported from PubMed on 21 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement